StockNews.com upgraded shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) from a hold rating to a buy rating in a research report sent to investors on Monday morning. A number of other equities analysts also recently weighed in on the company. Raymond James cut their target price on ProQR Therapeutics from $5.00 to $4.00 and […]